QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ACRS

QT55Aclaris Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.50
+0.08+1.81%
OverviewShort InterestFilings
ACRSQT55Aclaris Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
4.50+1.81%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.56
Insider Own14.60%
Shs Outstand139.66M
Perf Week2.97%
Market Cap533.03MForward P/E-EPS next Y-0.77Insider Trans0.50%Shs Float-Perf Month1.12%
Enterprise Value506.35MPEG-EPS next Q-0.16Inst Own-Short Float-Perf Quarter20.32%
Income-65242860.00P/S63.71EPS this Y-19.48%Inst Trans-Short Ratio-Perf Half Y40.19%
Sales8.37MP/B3.96EPS next Y-14.63%ROA-35.06%Short Interest-Perf YTD49.50%
Book/sh1.03P/C-EPS next 5Y-ROE-55.89%52W High5.15 -12.62%Perf Year221.43%
Cash/sh0.75P/FCF-EPS past 3/5Y-ROIC-46.81%52W Low1.34 235.82%Perf 3Y-
Dividend Est.-EV/EBITDA-7.17Sales past 3/5Y-35.63% 5.92%Gross Margin76.34%Volatility3.86% 3.34%Perf 5Y-
Dividend TTM-EV/Sales60.52EPS Y/Y TTM67.25%Oper. Margin-961.91%ATR (14)0.25Perf 10Y-
Dividend Ex-Date-Quick Ratio4.03Sales Y/Y TTM-57.89%Profit Margin-832.58%RSI (14)52.39Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.03EPS Q/Q-25.00%SMA201.35%Beta0.55Target Price10.60
Payout0.00%Debt/Eq0.01Sales Q/Q100.00%SMA501.41%Rel Volume3.21Prev Close4.42
Employees61LT Debt/Eq0.02EarningsAug 06SMA20038.82%Avg Volume1.35MPrice4.50
IPO DateOct 06, 2015Option/ShortYes / YesEPS/Sales Surpr.6.25% 100.00%Net Debt/EBITDA0.38Volume4,322,614Change1.81%
Analyst Ratings
DateActionAnalystRatingTarget
May-05-26InitiatedGuggenheimBuy$12
May-05-26ReiteratedPiper SandlerOverweight$11
Apr-29-26ReiteratedWedbushOutperform$10
Apr-16-26InitiatedOppenheimerOutperform$10
Jan-30-26InitiatedCraig-Hallum$10
Dec-23-24UpgradeHC Wainwright & Co.Neutral → Buy
Nov-19-24UpgradeBTIGNeutral → Buy$8.00
Nov-19-24UpgradeLeerink PartnersMarket Perform → Outperform
Nov-19-24UpgradeJefferiesHold → Buy$7.00
Nov-18-24UpgradePiper SandlerNeutral → Overweight
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8819
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A223
Gross Profit7616
Selling, General and Administrative Excl. Other232222
Research and Development575334
Other Operating Expense77102
Operating Income-80-76-142
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-9-11-89
Net Income Before Taxes-70-65-132
Income Taxes000
Consolidated Net Income-70-65-132
Net Income From Continuing Operations-70-65-132
Net Income-70-65-132
EPS (Recurring)-0.56-0.53-1.71
EPS (Basic, Before Extraordinaries)-0.56-0.53-1.71
EPS (Diluted)-0.56-0.53-1.71
EBITDA-71-64-52
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio72.5646.28—
Gross Margin87.5075.0084.21
Operating Margin-1,000.00-950.00-747.37
Net Margin-875.00-812.50-694.74
Shares Outstanding12912377
Market Capitalization581370—
Operating Lease Expense
———
Insider Trading Volume
$4.84$4.47$4.10$3.72$3.35● Close Price0.00M0.34M0.68M1.02M1.36MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SCHIFF ANDREW NDirectorJun 05 '26Option Exercise0.0023,160025,540Jun 08 12:00 AM
Molineaux Christopher P.DirectorJun 05 '26Option Exercise0.0023,160069,536Jun 08 12:00 AM
Humphries William D.DirectorJun 05 '26Option Exercise0.0023,160045,105Jun 08 12:00 AM
MILANO VINCENTDirectorJun 05 '26Option Exercise0.0023,160028,896Jun 08 12:00 AM
Mehra AnandDirectorJun 05 '26Option Exercise0.0023,1600726,403Jun 08 12:00 AM
GOWEN MAXINEDirectorJun 05 '26Option Exercise0.0023,160033,334Jun 08 12:00 AM
Hall Jesse WayneChief Medical OfficerMay 01 '26Option Exercise0.0072,7500109,125May 05 12:00 AM
Leonard Braden Michael10% OwnerApr 23 '26Sale4.53300,0001,359,00013,950,000Apr 27 12:00 AM
Balthaser KevinChief Financial OfficerMar 01 '26Option Exercise0.004,7500188,130Mar 03 12:00 AM
Loerop JamesChief Business OfficerFeb 03 '26Option Exercise0.0041,7500198,197Feb 05 12:00 AM
Walker NealCEOFeb 03 '26Option Exercise0.00126,95001,562,497Feb 05 12:00 AM
Davis Hugh M.President and COOFeb 03 '26Option Exercise0.0037,350056,025Feb 05 12:00 AM
Balthaser KevinChief Financial OfficerFeb 03 '26Option Exercise0.0044,0500192,204Feb 05 12:00 AM
Loerop JamesChief Business OfficerFeb 01 '26Option Exercise0.0067,0000188,008Feb 05 12:00 AM
Balthaser KevinChief Financial OfficerFeb 01 '26Option Exercise0.0029,5000175,163Feb 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR